Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.70 TWD
594.83 M TWD
5.14 B TWD
340.51 M
About SYNMOSA BIOPHARMA CORP
Sector
CEO
Chih Hui Lin
Headquarters
Taipei
Website
Founded
1970
ISIN
TW0004114004
FIGI
BBG000P5V247
Synmosa Biopharma Corp. engages in the manufacture and sale of ethical drug, over-the-counter drug, and healthcare products under Synmosa's trade mark. The firm's products include drugs for hormone replacement treatment, cardiovascular, neurology, urology, hormonal oncology, oral contraceptive, and over-the-counter products. It operates through the Active Pharmaceutical Ingredients and Generic Drugs segments. The company was founded on August 25, 1970 and is headquartered in Taipei, Taiwan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4114 is 33.30 TWD — it has decreased by −0.45% in the past 24 hours. Watch SYNMOSA BIOPHARMA CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange SYNMOSA BIOPHARMA CORP stocks are traded under the ticker 4114.
4114 stock has fallen by −0.60% compared to the previous week, the month change is a −4.17% fall, over the last year SYNMOSA BIOPHARMA CORP has showed a −6.66% decrease.
4114 reached its all-time high on Dec 26, 2022 with the price of 42.20 TWD, and its all-time low was 2.05 TWD and was reached on Nov 20, 2006. View more price dynamics on 4114 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4114 stock is 0.90% volatile and has beta coefficient of 0.11. Track SYNMOSA BIOPHARMA CORP stock price on the chart and check out the list of the most volatile stocks — is SYNMOSA BIOPHARMA CORP there?
Today SYNMOSA BIOPHARMA CORP has the market capitalization of 13.83 B, it has decreased by −3.12% over the last week.
Yes, you can track SYNMOSA BIOPHARMA CORP financials in yearly and quarterly reports right on TradingView.
SYNMOSA BIOPHARMA CORP is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
4114 net income for the last quarter is 163.42 M TWD, while the quarter before that showed 202.37 M TWD of net income which accounts for −19.25% change. Track more SYNMOSA BIOPHARMA CORP financial stats to get the full picture.
Yes, 4114 dividends are paid annually. The last dividend per share was 0.60 TWD. As of today, Dividend Yield (TTM)% is 1.64%. Tracking SYNMOSA BIOPHARMA CORP dividends might help you take more informed decisions.
SYNMOSA BIOPHARMA CORP dividend yield was 1.55% in 2023, and payout ratio reached 37.25%. The year before the numbers were 1.15% and 22.89% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 22, 2024, the company has 446.00 employees. See our rating of the largest employees — is SYNMOSA BIOPHARMA CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SYNMOSA BIOPHARMA CORP EBITDA is 1.06 B TWD, and current EBITDA margin is 18.59%. See more stats in SYNMOSA BIOPHARMA CORP financial statements.
Like other stocks, 4114 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYNMOSA BIOPHARMA CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYNMOSA BIOPHARMA CORP technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYNMOSA BIOPHARMA CORP stock shows the neutral signal. See more of SYNMOSA BIOPHARMA CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.